Kalvista Pharmaceuticals Inc KALV
$27.00 $0.01 (0.04%) 1D
Last Updated: Jun 10, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
KALV Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Kalvista Pharmaceuticals Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Kalvista Pharmaceuticals Inc. Stock Analysis KALV
United States Health Care Small Cap KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Framingham, Massachusetts and currently employs 275 full-time employees. The company went IPO on 2015-04-09. The company has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Kalvista Pharmaceuticals Inc (KALV) Chart
Financial Metrics & Statements of Kalvista Pharmaceuticals Inc (KALV)
FAQ's for Kalvista Pharmaceuticals Inc (KALV)
- As of August 2026, Kalvista Pharmaceuticals Inc KALV is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kalvista Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kalvista Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kalvista Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kalvista Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kalvista Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Kalvista Pharmaceuticals Inc (KALV)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
